Drug Profile
3-antigen Staphylococcus aureus vaccine - Pfizer
Alternative Names: 3-antigen Staphylococcus aureus vaccine - Inhibitex/Pfizer; PF-05230894; PF-5230894; SA3Ag; Staph vaccine - Inhibitex/Pfizer; Staphylcoccus aureus vaccine - Inhibitex/Pfizer; Staphylococcus aureus vaccine (3-antigen) - Pfizer; WYE-400062Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Staphylococcal infections
Most Recent Events
- 10 Nov 2011 Discontinued - Phase-I for Staphylococcal infections in Australia (IM)
- 08 Aug 2011 Phase-I/II clinical trials in Staphylococcal infections in USA (IM)
- 31 Jul 2011 Pfizer completes a phase I trial in healthy volunteers in Australia (NCT01018641)